Dublin, Nov. 20, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/2r3q8d/metabolomics)
has announced the addition of the "Metabolomics
(Biomarker Discovery/Metabolite Detection/Metabolite Profiling)
Market By Applications (Drug Discovery/Toxicology Assessment/
Diagnosis) and Indications (Oncology/Cardiology/Neurology) -
Forecasts from 2012 to 2017" report to their offering.
Over the last decade, genomics and proteomics have been used as key
tools to discover potential drug targets and to better understand
the complexities of biology. To balance research in these areas,
metabolomics, a new science is evolving for analyzing the basic
metabolic changes taking place in a living organism. Metabolomics
is thus an emerging concept which refers to the systematic study of
the distinctive chemical fingerprints generated in a particular
cellular process.
Metabolomics Market - Analysis of Global Technology, Application
Trends and Landscape 2012-2017 report covers the market by disease
indications along with the applications and metabolite profiling
for biomarker discovery applications. In addition, it also includes
the factors driving and restraining the market and covers the
market scenario in the U.S., Europe, Asia and the Rest of the World
(ROW). This report will provide the company profiles of key
companies along with the competitive analysis.
The Global Metabolomics
market is showing a double digit growth (CAGR 35%) due to
supportive factors such as, (i) increased willingness of
biotechnology and pharma companies to adopt metabolomics concept to
drive R&D activity within the industry, (ii) rapid growth of
metabolomics data analysis softwares and solutions, and (iii) the
advancement of analytical technologies. Metabolomics is used in the
identification of new biomarkers, which indicate a change in the
physiological state of a cell or tissue. Biomarker screening is
important in the process of new drug discovery, and is also a key
in vitro diagnostics tool. Additionally it is also being used for
environmental toxicology screening. While, there are major concerns
of this market such as the validation challenges, the positive
aspects may very well offset the market restraints to aid the
market grow at an exceptional rate.
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Metabolomics -Technology Landscape Analysis
4. Metabolomics - Market Landscape Analysis
5. Metabolomics - Technology Investment Potential
6. Metabolomics - Geographical Analysis
7. Competitive Landscape Analysis
8. Patent Analysis
9. Technology Analysis (Using Multi Criteria Decision Making) & Road Mapping
10 Analyst Insights & Recommendations
11 Company Profiles
12 Appendix
13 Glossary
Companies Mentioned
- Agilent Technologies
- Ab Sciex
- Accelrys
- Astrazeneca Plc
- Bio-Rad Laboratories
- Bruker Corporation
- Biocrates Life Sciences Ag
- Chenomx
- Eisai Co. Ltd.
- Human Metabolome Technologies
- Metabolomx
- Metanomics Gmbh
- Metabolomic Technologies
- Metabolon
- Nextgen Metabolomics
- Phenomenome
- Research Institute Of Chromatography (Ric)
- Shimadzu Corporation
- Stemina Biomarker
- Sidmap, Llc
- Waters Corporation
For more information visit http://www.researchandmarkets.com/research/2r3q8d/metabolomics
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Healthcare and Medical Devices